Formulation of insulin-loaded polymeric nanoparticles using response surface methodology

被引:45
作者
Attivi, D
Wehrle, P
Ubrich, N
Damge, C
Hoffman, M
Maincent, P
机构
[1] Fac Pharm, Lab Pharmacotech, F-67401 Illkirch Graffenstaden, France
[2] Fac Pharm Nancy, Lab Pharm Galen & Biopharm, Nancy, France
[3] Fac Med, Ctr Europeen Etud Diabete, Strasbourg, France
关键词
W/O/W emulsion; nanoparticles; PCL; Eudragit RS; insulin; response surface methodology; experimental design;
D O I
10.1081/DDC-200047802
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The Objective of this work was to formulate new oral insulinloaded nanoparticules using the response surface methodology. The insulin nanoparticles were prepared by a water-in-oil-in-water emulsification and evaporation method. The polymers used for the encapsulation were blends of biodegradable poly-epsilon-caprolactone (PCL) and of positively-charged, nonbiodegradable polymer (Eudragis RS(R)). A central composite design has been built to investigate the effects of three controlled variables: ratio of polymers (PCL/RS ratio), volume, and pH of the aqueous solution of polyvinyl alcohol. The nanoparticles were characterized by measuring the amount of entrapped insulin, the particle size, the polydispersity of the obtained particles, the zeta potential, and the amount of insulin released after 7 hours. A second-order model was evaluated by multiple regression and was statistically tested for each of the studied controlled variable The obtained. polynomials proved efficient to localize an optimal operating area highlighted by the use of three-dimensional response surfaces and their corresponding isoresponse curves. An interesting formulation given by the models was selected, prepared, and evaluated. The corresponding quantity of entrapped insulin was 25 IU per 100 mg of polymer, and the particle size was 350 nm with a polydispersity of 0.21. The quantity of released insulin was 4.8 lU per 100 mg of polymer after 7 hours and the zeta potential was +44 mV. All these collected values were in perfect accordance with values estimated by the models. Finally, the results suggested that PCL/RS 50/50 nanoparticles might represent a promising formulation for oral delivery of insulin.
引用
收藏
页码:179 / 189
页数:11
相关论文
共 14 条
  • [1] Box G, 1987, EMPIRICAL MODEL BUIL
  • [2] CARSLEDT I, 1984, CIBA FDN S, V109
  • [3] Effect of the type of hydrophobic polymers on the size of nanoparticles obtained by emulsification-solvent evaporation
    Chernysheva, YV
    Babak, VG
    Kildeeva, NR
    Boury, F
    Benoit, JP
    Ubrich, N
    Maincent, P
    [J]. MENDELEEV COMMUNICATIONS, 2003, (02) : 65 - 68
  • [4] NEW APPROACH FOR ORAL-ADMINISTRATION OF INSULIN WITH POLYALKYLCYANOACRYLATE NANOCAPSULES AS DRUG CARRIER
    DAMGE, C
    MICHEL, C
    APRAHAMIAN, M
    COUVREUR, P
    [J]. DIABETES, 1988, 37 (02) : 246 - 251
  • [5] PROMOTING EFFECT OF THE NEW CHYMOTRYPSIN INHIBITOR FK-448 ON THE INTESTINAL-ABSORPTION OF INSULIN IN RATS AND DOGS
    FUJII, S
    YOKOYAMA, T
    IKEGAYA, K
    SATO, F
    YOKOO, N
    [J]. JOURNAL OF PHARMACY AND PHARMACOLOGY, 1985, 37 (08) : 545 - 549
  • [6] Interaction of a self-emulsifying lipid drug delivery system with the everted rat intestinal mucosa as a function of droplet size and surface charge
    Gershanik, T
    Benzeno, S
    Benita, S
    [J]. PHARMACEUTICAL RESEARCH, 1998, 15 (06) : 863 - 869
  • [7] Low molecular weight heparin-loaded polymeric nanoparticles: Formulation, characterization, and release characteristics
    Hoffart, V
    Ubrich, N
    Simonin, C
    Babak, V
    Vigneron, C
    Hoffman, M
    Lecompte, T
    Maincent, P
    [J]. DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2002, 28 (09) : 1091 - 1099
  • [8] In vitro and in vivo evaluation of oral heparin-loaded polymeric nanoparticles in rabbits
    Jiao, YY
    Ubrich, N
    Marchand-Arvier, M
    Vigneron, C
    Hoffman, M
    Lecompte, T
    Maincent, P
    [J]. CIRCULATION, 2002, 105 (02) : 230 - 235
  • [9] Lewis G. A., 1999, PHARM EXPT DESIGN
  • [10] ENHANCED INTESTINAL-ABSORPTION OF INSULIN IN RATS IN THE PRESENCE OF SODIUM 5-METHOXYSALICYLATE
    NISHIHATA, T
    RYTTING, JH
    KAMADA, A
    HIGUCHI, T
    [J]. DIABETES, 1981, 30 (12) : 1065 - 1067